Peter WF Wilson, MD
Pamela S Douglas, MD
Joseph S Alpert, MD
Michael Simons, MD
Jeffrey A Breall, MD, PhD
Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC
Patricia A Pellikka, MD, FACC, FAHA, FASE
Juan Carlos Kaski, MD, DM, DSc, FRCP, FESC, FACC, FAHA
Christopher P Cannon, MD
Allan S Jaffe, MD
Disclosures: Peter WF Wilson, MD Nothing to disclose. Pamela S Douglas, MD Grant/Research/Clinical Trial Support: Abiomed [Heart failure (Right ventricular percutaneous assist device)]; Atritech/Boston Scientific [Atrial fibrillation (Left atrial appendage occlude device)]; Bristol Meyers Squibb [Hepatitis]; David H Murdock Research Institute; Gilead [Hepatitis (Sofusbivir)]; Edwards Lifesciences [Aortic Stenosis (Percutaneous heart valve)]; HeartFlow [Coronary artery disease (CTA analysis software)]; Ikaria [Heat failure (Sodium alginate)]; Merck; Novartis; ResMed [Heart failure (Ventilator)]; Roche [Heart failure]; Stealth Peptides [Heart failure (D-arginyl-2’,6’-dimethyl-L-tyrosyl- L –lysyl- L –phenylalaninamide)]. Consultant/Advisory Boards: Boston Scientific [Atrial fibrillation (Left atrial appendage occlude device)]; CardioDx [Coronary artery disease (Blood diagnostic with gene expression)]; Interleukin Genetics; Pappas Ventures; Omicia [Genomics]; Third Point, LLC; Genome Magazine [Genomics]; US Diagnostic Standards [Genomic testing]. Equity Ownership/Stock Options: CardioDx [Coronary artery disease (Blood diagnostic with gene expression)]; Omicia [Genomics]. Joseph S Alpert, MD Nothing to disclose. Michael Simons, MD Nothing to disclose. Jeffrey A Breall, MD, PhD Consultant/Advisory Boards: Siemens [Interventional Cardiology (cath lab equipment)]. Employment: Fujifilm [CPACs systems (Synapse CV - image and report archiving)]. Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC Consultant/Advisory Boards: Medtronic [Cardiovascular (Member of Reveal Steering Committee)]; Baxter Healthcare Corporation [Cardiovascular (Clinical development of autologous CD34+ stem cells)]; Cardiovascular Research Foundation [Cardiovascular (Symplicity HTN-3 trial and MASTER II trial)]; St. Jude Medical [Cardiovascular (FAME II Trial)]; Ortho-McNeill Janssen Scientific Affairs [Cardiovascular (Member of Executive Committee)]; TEVA Pharmaceuticals [Cardiovascular (Chairman of DSMB on stem cell trial)]; Boston Scientific [Cardiovascular (Transcutaneous aortic valve replacement trial)]. Patricia A Pellikka, MD, FACC, FAHA, FASE Nothing to disclose. Juan Carlos Kaski, MD, DM, DSc, FRCP, FESC, FACC, FAHA Nothing to disclose. Christopher P Cannon, MD Grant/Research Support: Accumetrics (Platelets and ACS [Verify Now platelet test]); Arisaph (Lipids); AstraZeneca (ACS, lipids, and GI [Ticagrelor, Rosuvastatin, PPI]); Boehringer-Ingelheim (AF [Dabigatran]); CSL Behring (Lipids); Essentialis (Lipids); GlaxoSmithKline (Lipids and DM); Janssen (AF and DM [Rivaroxaban and Cangliflozen); Merck (Lipids [Ezetimibe]); Regeneron (Lipids); Sanofi (Lipids and ACS [clopidogrel]); Takeda (DM [Pioglitazone]). Consultant/Advisory Boards: Bristol-Myers Squibb (AF [Apixaban]); Lipimedix (Lipids); Pfizer (AF, DM, and Lipids [Apixaban, Etrugliflozin, Atorvastatin]). Allan S Jaffe, MD Consultant/Advisory Boards: Beckman; Alere; Abbott; Critical Dx; Trinity; ET Healthcare; Roche; Siemens; Radiometer; Amgen; theheart.org [Biomarkers (Diagnostic tests)]. Gordon M Saperia, MD, FACC Employee of UpToDate, Inc.
Contributor disclosures are reviewed for conflicts of interest by the editorial group. When found, these are addressed by vetting through a multi-level review process, and through requirements for references to be provided to support the content. Appropriately referenced content is required of all authors and must conform to UpToDate standards of evidence.
INTRODUCTION — Survivors of a first acute myocardial infarction (MI) face a substantial risk of further cardiovascular events, including death, recurrent MI, heart failure, arrhythmias, angina, and stroke. Patients (and family members) often ask what their future holds; thus, information regarding prognosis after MI is necessary for patient care.
The outcomes discussed in this topic, such as mortality, are presented using pooled data. However, the prognosis may vary widely between individuals, according to the presence or absence of risk factors present before the MI. These risk factors are discussed elsewhere. (See "Risk factors for adverse outcomes after non-ST elevation acute coronary syndromes" and "Risk factors for adverse outcomes after ST-elevation myocardial infarction".)
The likelihood of subsequent events presented here are rough estimates. For most patients with MI, clinicians should risk stratify them using validated risk prediction models. This process is described in detail separately. (See "Risk stratification after acute ST-elevation myocardial infarction" and "Risk stratification after non-ST elevation acute coronary syndrome".)
The discussion of sudden cardiac death following MI is found elsewhere. (See "Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction" and 'Adverse non-fatal outcomes' below.)
SHORT-TERM OUTCOMES — Reported outcomes, and in particular, mortality, will vary based on the population studied. While many of the reports come from randomized trials, we consider outcomes reported from registries to be a better gauge. Registries usually include broad populations, whereas trial participation is often limited by inclusion/exclusion criteria.
Mortality — Across the broad spectrum of patients with acute myocardial infarction (MI), short-term (in-hospital or 30-day) mortality has been decreasing over the past 30 years, concomitantly with the increasing use of reperfusion strategies and proven preventative therapies such as beta blockers, aspirin, and statins [1-9]. (See "Acute ST elevation myocardial infarction: Selecting a reperfusion strategy" and "Trials of conservative versus early invasive therapy in unstable angina and non-ST elevation myocardial infarction" and "Secondary prevention of cardiovascular disease".)
The current 30-day mortality after all acute coronary syndromes (ST-elevation myocardial infarction [STEMI], non-ST elevation myocardial infarction [NSTEMI], and unstable angina) is probably in the 2 to 3 percent range, but likely around 5 percent if patients with unstable angina are not included . (See "Overview of the acute management of ST elevation myocardial infarction".)
In a report that evaluated the interval 1987 to 2002, the 28-day case fatality fell from 5.3 to 3.8 percent . A similar trend was noted in an analysis of data on 2.5 million patients from the National Registry of Myocardial Infarction in which in-hospital mortality after an acute MI declined from 10.4 percent in 1994 to 6.3 percent in 2006 .
STEMI — The 30-day mortality rate of patients with STEMI is between 2.5 and 10 percent in reports [10,12-15].
Both in-hospital and 30-day mortality rates after STEMI have been lower in clinical trials compared to registries and reports in patients not in clinical trials. This has been explained by enrollment of a lower risk population and better adherence to proven therapies in the former. Among patients with STEMI enrolled in trials, approximate in-hospital or 30-day mortality rates were 13 percent with medical therapy alone, 6 to 7 percent with optimal fibrinolytic therapy [16,17], and as low as 3 to 5 percent with primary percutaneous coronary intervention (PCI) when performed within two hours of chest pain onset [14,18,19]. (See "Characteristics of fibrinolytic (thrombolytic) agents and clinical trials in acute ST elevation myocardial infarction" and "Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome", section on 'Time from hospital arrival (door-to-balloon time)'.)
Somewhat higher in-hospital and 30-day mortality rates after STEMI have been described in patients not enrolled in clinical trials and cared for during a similar time period. The reported in-hospital mortality has been reported between 7 and 9.7 percent and the 30-day mortality between 11.1 and 14 percent for patients [15,20,21]. A number of factors could contribute to this difference, including patient selection, less frequent use of appropriate therapies, and data collection before trials, supporting the value of primary PCI [15,20-22].
More contemporary reports of patients not enrolled in trials have documented a continued decline in mortality in STEMI patients [12,13,23]. For example, outcomes were presented in a 2012 report of 6707 STEMI patients in four French nationwide registries conducted five years apart (1995, 2000, 2005, and 2010) . The following findings were noted:
●There were significant decreases in crude 30-day mortality (from 13.7 to 4.4 percent) and mortality standardized to 2010 population characteristics (from 11.3 to 4.4 percent). These declines were seen irrespective of the type of reperfusion (fibrinolysis or PCI) and in patients who were not reperfused.
●Time from symptom onset to hospital admission decreased, with a shorter time from onset to first call, and broader use of mobile intensive care units.
●During this time, the average age fell and the prevalence of most risk factors increased
●The use of reperfusion therapy increased from 50 to 75 percent, driven mostly by an increase of the use of PCI, as did the use of recommended preventative medical therapies.
●Within the STEMI population assessed in these registries, the relative proportion of older patients decreased, and the proportion of younger men and women increased. These registry data suggest that future strategies aimed at further reducing acute MI incidence and mortality will need to specifically target prevention in younger men and women. (See "Secondary prevention of cardiovascular disease".)
NSTEMI — Among patients with a non-ST elevation acute coronary syndrome (ACS), in-hospital or 30-day mortality has been about 2 percent in major clinical trials, lower than that seen in STEMI [25,26]. Although an early invasive strategy is now performed in most patients, because of reductions in recurrent MI or rehospitalization for an ACS, mortality rates in randomized trials were not significantly reduced in-hospital (or at six months) by this strategy [25,26]. (See "Trials of conservative versus early invasive therapy in unstable angina and non-ST elevation myocardial infarction".)
The following studies include the range of findings for patients not enrolled in randomized controlled clinical trials:
●In the GRACE registry of over 16,000 patients from 14 countries seen between 2001 and 2007, the in-hospital mortality was 3.3 percent with non-ST elevation ACS (NSTEACS) .
●In the French registry of 1645 patients with NSTEMI managed with an invasive strategy in 2005, the in-hospital mortality was 2.0 percent .
●In the Worcester (Massachusetts, United States) Heart Attack Study, the hospital and 30-day post-admission case fatality rates for 2005 were 9.5 and 14.0 percent, respectively .
STEMI versus NSTEMI — Short-term mortality is lower in patients with NSTEMI (2 to 4 percent) compared to patients with STEMI (3 to 8 percent) treated with primary PCI within two hours of hospital arrival [10,18,19,21,25,26,30]. The American College of Cardiology National Cardiovascular Data Registry collects information on patients who undergo cardiac catheterization and PCI in the United States . The risk-adjusted in-hospital mortality between 2007 and 2009 for the subset of acute MI patients who underwent PCI was about 6 percent for STEMI and about 4 percent for NSTEMI. For both types of MI, there were trends toward lower mortality with time.
Better short-term outcomes for patients with NSTEMI have also been noted in other studies (eg, in-hospital mortality 5 to 7 percent compared with 7.0 to 9.3 percent with STEMI in the GRACE and Euro Heart registries) [20,21,25].
Adverse non-fatal outcomes — Besides death, other patient-important outcomes include stroke, recurrent MI, heart failure, and major bleeding. In the GRACE registry of patients with NSTEACS discussed above, the rates of in-hospital heart failure or shock, MI, major bleeding, or stroke were 10, 2.4, 1.8, and 0.5 percent, respectively . In the HORIZONS AMI randomized trial, the rate of stroke was around 1 percent and the rate of reinfarction was about 2 percent at 30 days . (See "Anticoagulant therapy in acute ST elevation myocardial infarction", section on 'UFH compared to bivalirudin'.)
Early rehospitalization — The rate of rehospitalization within 30 days after acute MI is reported to range between 17 and 25 percent [31,32]. In a single-community (Olmsted County, Minnesota, United States) study of 3010 patients who were hospitalized for a first-ever MI (31 percent STEMI) between 1987 and 2010, rehospitalization within 30 days occurred in about 19 percent . Of these, 30 percent were and 43 percent were not related to the incident event. Diabetes, chronic obstructive pulmonary disease, anemia, higher Killip class (table 1), longer length of stay during the index hospitalization, and a complication of angiography or reperfusion or revascularization were associated with increase rehospitalization risk.
− Similar to short-term outcomes, long-term mortality rates after myocardial infarction (MI) have declined significantly during the past 30 years due to reperfusion and preventative strategies. In an analysis of 23 published studies in which follow-up was completed prior to 1980, the death rate was about 28 percent at five years . A report had a five-year death rate of about 21 percent in patients treated between 1989 and 1993 .
In contrast to the short-term outcomes, which are worse with ST-elevation MI (STEMI), long-term outcomes have been similar or worse with non-ST elevation myocardial infarction (NSTEMI) [2,25,36-40]. The largest direct comparison comes from the GUSTO-IIb trial performed in the early 1990s of 12,142 patients with STEMI, NSTEMI (using only creatine kinase MB fraction, not troponins, for diagnosis), or unstable angina . The mortality rate at 30 days was lower with NSTEMI than STEMI (3.8 versus 6.1 percent). In contrast, the mortality at one year was similar (8.8 for NSTEMI versus 9.6 percent for STEMI). However, outcomes from patients with NSTEMI managed more recently were lower in the ISAR REACT 4 trial, in which mortality at one year was about 4.4 percent. (See "Anticoagulant therapy in non-ST elevation acute coronary syndromes", section on 'Bivalirudin'.)
In a community-based observational study of almost 6000 first MIs over a 23-year period, patients with an NSTEMI (compared to those with STEMI) had higher two-year mortality (20 versus 11 percent) . Other registry reports suggest that, at one and two years, the cumulative mortality for NSTEMI exceeds that of STEMI patients. In the OPERA registry, cardiovascular outcomes were evaluated in 2151 consecutive patients (71 percent STEMI) with confirmed MI during 2002 and 2003 . The STEMI patients were treated with primary percutaneous coronary intervention (PCI) (71 percent) or fibrinolytic therapy (29 percent), while PCI was performed in 52 percent of NSTEMI patients. In-hospital mortality was not different for both groups (4.6 versus 4.3 percent), while the one-year post-discharge mortality was higher with NSTEMI (8.2 versus 5.0 percent). In a report for the Worcester (Massachusetts, United States) Heart Attack Study, the one-year post-discharge case fatality rates in 2005 for patients with STEMI and NSTEMI were 8.4 and 18.7 percent, respectively .
Further evidence suggesting worse long-term outcomes with NSTEMI comes from a comparison of two studies that evaluated outcomes separately. A French registry evaluated outcomes in 1645 patients with NSTEMI managed with an invasive strategy during 2005 and found that mortality at three years was approximately 20 percent, with about half the deaths due to cardiovascular causes . However, mortality at three years was around 6 to 7 percent in the HORIZONS AMI trial of patients with STEMI who underwent primary PCI . (See "Anticoagulant therapy in acute ST elevation myocardial infarction", section on 'UFH compared to bivalirudin'.)
The similar or worse long-term prognosis in NSTEMI is in part related to more than a 50 percent prevalence of multivessel disease in affected patients and to a greater likelihood of residual ischemia [36,43,44], indicating that in these patients, a significant amount of myocardium often remains at risk.
Sudden cardiac death — The broad discussion of sudden cardiac death (SCD) and sudden cardiac arrest is found elsewhere. (See "Epidemiology of coronary heart disease", section on 'Sudden cardiac death' and "Overview of sudden cardiac arrest and sudden cardiac death" and "Pathophysiology and etiology of sudden cardiac arrest" and "Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction".)
The incidence of SCD after acute MI is the same with STEMI and NSTEMI [1,45]. Among patients who have had an MI and are followed for about four years, approximately one-half of sudden deaths occur in the first year and one-quarter in the first three months [46,47]. The risk is markedly increased in patients with a left ventricular ejection fraction ≤35 percent. (See "Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction", section on 'Incidence of SCD'.)
Adverse non-fatal outcomes — While most patients are concerned about survival, many ask questions about other clinically important outcomes:
●Angina − A study of nearly 2000 patients who sustained an MI in 2003 or 2004 found that angina occurred in nearly 20 percent as early as one year and the determinants were younger age, nonwhite race and male sex, prior angina, angina during the hospital stay, smoking continuation, depression, and coronary artery bypass graft surgery history .
●Recurrent MI and stroke – In the HORIZONS AMI trial, the risk of reinfarction or stroke at three years was approximately 6 to 7 and 1.5 to 2 percent, respectively . (See "Anticoagulant therapy in acute ST elevation myocardial infarction", section on 'UFH compared to bivalirudin'.)
Risk after an MI is not the same for all patients and prognosis can be estimated in the outpatient setting for survivors. The GRACE Study investigated subjects at the time of an acute coronary syndrome event and the key variables were age, heart rate, systolic pressure, creatinine, congestive heart failure, cardiac arrest at admission, ST segment deviation, and cardiac enzymes . Other investigators have evaluated prognosis when the baseline evaluation is more than several months after a vascular disease event. For example, a report based on the two-year post-MI experience of 49,689 REACH Registry participants from around the world has shown that recurrent cardiovascular (CVD) disease and CVD death can be predicted with a simple algorithm. The core variables in the REACH prediction model were age, male sex, presence of peripheral vascular disease or cerebrovascular disease, diabetes, smoking, low body mass index, history of atrial fibrillation, cardiac failure, history of a CVD event in the past year, and favorable effects on risk were seen for statins and aspirin .
Similarly, in the SMART Study, after 4.7 years of follow-up for 5788 Dutch adults with coronary disease, peripheral arterial disease, or cerebrovascular disease at baseline, the key predictor variables for recurrent vascular disease were age, male sex, smoking, systolic pressure, total cholesterol, high density lipoprotein-cholesterol, high sensitivity C-reactive protein, estimated glomerular filtration rate, and years since first vascular event .
INFORMATION FOR PATIENTS — UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
●Basics topics (see "Patient information: Heart attack recovery (The Basics)")
●Beyond the Basics topics (see "Patient information: Heart attack recovery (Beyond the Basics)")
●Survivors of a myocardial infarction (MI) face a substantial excess risk of further cardiovascular events, including an increase in mortality. However, the prognosis for an individual varies markedly according to the presence or absence of adverse risk factors. (See 'Introduction' above.)
●Short- and long-term death rates following MI have fallen substantially in the past few decades with improvements in medical care, particularly the widespread use of reperfusion techniques and the adjunctive use of multiple medical therapies. (See 'Short-term outcomes' above and 'Mortality' above.)
●The current 30-day mortality after all acute coronary syndromes (ST-elevation myocardial infarction [STEMI], non-ST elevation myocardial infarction [NSTEMI], and unstable angina) is probably in the 2 to 3 percent range, but likely around 5 percent if patients with unstable angina are not included. (See 'Mortality' above.)
●Short-term mortality is lower in patients with NSTEMI (2 to 4 percent) compared to patients with STEMI (3 to 8 percent) treated with primary percutaneous coronary intervention within two hours of hospital arrival. (See 'STEMI versus NSTEMI' above.) Long-term mortality is similar or worse with NSTEMI. At one year, mortality is around 5 to 9 percent. (See 'Mortality' above.)
- Rosamond WD, Chambless LE, Folsom AR, et al. Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. N Engl J Med 1998; 339:861.
- Furman MI, Dauerman HL, Goldberg RJ, et al. Twenty-two year (1975 to 1997) trends in the incidence, in-hospital and long-term case fatality rates from initial Q-wave and non-Q-wave myocardial infarction: a multi-hospital, community-wide perspective. J Am Coll Cardiol 2001; 37:1571.
- Rogers WJ, Canto JG, Lambrew CT, et al. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3. J Am Coll Cardiol 2000; 36:2056.
- Heidenreich PA, McClellan M. Trends in treatment and outcomes for acute myocardial infarction: 1975-1995. Am J Med 2001; 110:165.
- Fang J, Alderman MH. Dissociation of hospitalization and mortality trends for myocardial infarction in the United States from 1988 to 1997. Am J Med 2002; 113:208.
- Velagaleti RS, Pencina MJ, Murabito JM, et al. Long-term trends in the incidence of heart failure after myocardial infarction. Circulation 2008; 118:2057.
- Rogers WJ, Frederick PD, Stoehr E, et al. Trends in presenting characteristics and hospital mortality among patients with ST elevation and non-ST elevation myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006. Am Heart J 2008; 156:1026.
- Gibson CM, Pride YB, Frederick PD, et al. Trends in reperfusion strategies, door-to-needle and door-to-balloon times, and in-hospital mortality among patients with ST-segment elevation myocardial infarction enrolled in the National Registry of Myocardial Infarction from 1990 to 2006. Am Heart J 2008; 156:1035.
- Krumholz HM, Wang Y, Chen J, et al. Reduction in acute myocardial infarction mortality in the United States: risk-standardized mortality rates from 1995-2006. JAMA 2009; 302:767.
- Roe MT, Messenger JC, Weintraub WS, et al. Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention. J Am Coll Cardiol 2010; 56:254.
- Myerson M, Coady S, Taylor H, et al. Declining severity of myocardial infarction from 1987 to 2002: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2009; 119:503.
- Rosamond WD, Chambless LE, Heiss G, et al. Twenty-two-year trends in incidence of myocardial infarction, coronary heart disease mortality, and case fatality in 4 US communities, 1987-2008. Circulation 2012; 125:1848.
- Jernberg T, Johanson P, Held C, et al. Association between adoption of evidence-based treatment and survival for patients with ST-elevation myocardial infarction. JAMA 2011; 305:1677.
- Tobbia P, Brodie BR, Witzenbichler B, et al. Adverse event rates following primary PCI for STEMI at US and non-US hospitals: three-year analysis from the HORIZONS-AMI trial. EuroIntervention 2013; 8:1134.
- McManus DD, Gore J, Yarzebski J, et al. Recent trends in the incidence, treatment, and outcomes of patients with STEMI and NSTEMI. Am J Med 2011; 124:40.
- An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med 1993; 329:673.
- Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators, Van De Werf F, Adgey J, et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 1999; 354:716.
- Cannon CP, Gibson CM, Lambrew CT, et al. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA 2000; 283:2941.
- Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002; 346:957.
- Steg PG, Goldberg RJ, Gore JM, et al. Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). Am J Cardiol 2002; 90:358.
- Hasdai D, Behar S, Wallentin L, et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J 2002; 23:1190.
- Bahit MC, Cannon CP, Antman EM, et al. Direct comparison of characteristics, treatment, and outcomes of patients enrolled versus patients not enrolled in a clinical trial at centers participating in the TIMI 9 Trial and TIMI 9 Registry. Am Heart J 2003; 145:109.
- Yeh RW, Sidney S, Chandra M, et al. Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med 2010; 362:2155.
- Puymirat E, Simon T, Steg PG, et al. Association of changes in clinical characteristics and management with improvement in survival among patients with ST-elevation myocardial infarction. JAMA 2012; 308:998.
- Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet 1999; 354:708.
- Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001; 344:1879.
- Brieger D, Fox KA, Fitzgerald G, et al. Predicting freedom from clinical events in non-ST-elevation acute coronary syndromes: the Global Registry of Acute Coronary Events. Heart 2009; 95:888.
- Puymirat E, Taldir G, Aissaoui N, et al. Use of invasive strategy in non-ST-segment elevation myocardial infarction is a major determinant of improved long-term survival: FAST-MI (French Registry of Acute Coronary Syndrome). JACC Cardiovasc Interv 2012; 5:893.
- Floyd KC, Yarzebski J, Spencer FA, et al. A 30-year perspective (1975-2005) into the changing landscape of patients hospitalized with initial acute myocardial infarction: Worcester Heart Attack Study. Circ Cardiovasc Qual Outcomes 2009; 2:88.
- Joynt KE, Orav EJ, Jha AK. Thirty-day readmission rates for Medicare beneficiaries by race and site of care. JAMA 2011; 305:675.
- Curtis JP, Schreiner G, Wang Y, et al. All-cause readmission and repeat revascularization after percutaneous coronary intervention in a cohort of medicare patients. J Am Coll Cardiol 2009; 54:903.
- Dunlay SM, Weston SA, Killian JM, et al. Thirty-day rehospitalizations after acute myocardial infarction: a cohort study. Ann Intern Med 2012; 157:11.
- Law MR, Watt HC, Wald NJ. The underlying risk of death after myocardial infarction in the absence of treatment. Arch Intern Med 2002; 162:2405.
- Bata IR, Gregor RD, Wolf HK, Brownell B. Trends in five-year survival of patients discharged after acute myocardial infarction. Can J Cardiol 2006; 22:399.
- Armstrong PW, Fu Y, Chang WC, et al. Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb Investigators. Circulation 1998; 98:1860.
- Behar S, Haim M, Hod H, et al. Long-term prognosis of patients after a Q wave compared with a non-Q wave first acute myocardial infarction. Data from the SPRINT Registry. Eur Heart J 1996; 17:1532.
- Haim M, Behar S, Boyko V, et al. The prognosis of a first Q-wave versus non-Q-wave myocardial infarction in the reperfusion era. Am J Med 2000; 108:381.
- Yan AT, Tan M, Fitchett D, et al. One-year outcome of patients after acute coronary syndromes (from the Canadian Acute Coronary Syndromes Registry). Am J Cardiol 2004; 94:25.
- Singh M, Reeder GS, Jacobsen SJ, et al. Scores for post-myocardial infarction risk stratification in the community. Circulation 2002; 106:2309.
- Montalescot G, Dallongeville J, Van Belle E, et al. STEMI and NSTEMI: are they so different? 1 year outcomes in acute myocardial infarction as defined by the ESC/ACC definition (the OPERA registry). Eur Heart J 2007; 28:1409.
- Stone GW, Witzenbichler B, Guagliumi G, et al. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet 2011; 377:2193.
- Liebson PR, Klein LW. The non-Q wave myocardial infarction revisited: 10 years later. Prog Cardiovasc Dis 1997; 39:399.
- Wang CH, Cherng WJ, Hua CC, Hung MJ. Prognostic value of dobutamine echocardiography in patients after Q-wave or non-Q-wave acute myocardial infarction. Am J Cardiol 1998; 82:38.
- Kannel WB, Cupples LA, D'Agostino RB. Sudden death risk in overt coronary heart disease: the Framingham Study. Am Heart J 1987; 113:799.
- Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002; 105:1897.
- Torp-Pedersen C, Køber L. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. Lancet 1999; 354:9.
- Maddox TM, Reid KJ, Spertus JA, et al. Angina at 1 year after myocardial infarction: prevalence and associated findings. Arch Intern Med 2008; 168:1310.
- Eagle KA, Lim MJ, Dabbous OH, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA 2004; 291:2727.
- Wilson PW, D'Agostino R Sr, Bhatt DL, et al. An international model to predict recurrent cardiovascular disease. Am J Med 2012; 125:695.
- Dorresteijn JA, Visseren FL, Wassink AM, et al. Development and validation of a prediction rule for recurrent vascular events based on a cohort study of patients with arterial disease: the SMART risk score. Heart 2013; 99:866.